Current Editions
With numbers flat vs 2024, the decline seems over — another sign the thaw is real
Finance
From muscarinic breakthroughs to next-gen psychedelics, what’s changing — and what isn’t — in the search for psychiatry medicines: The BioCentury Show
Product Development
Different points of pathway intervention in Gaucher vs. Fabry may be
Product Development
FDA must prevent mass compounding of approved drugs to protect patients and investment in innovative drugs
Editor's Commentary
HHS budget law revives pediatric PRVs, increases PBM transparency
Politics, Policy & Law
Product Development
Once-monthly GLP1R agonist from Metsera deal may require higher dose in Phase III to differentiate
Emerging Company Profile
Former DeepMind team building frontier models to design drug-like biologics for challenging targets in one step
Data Byte
Sanofi’s Rezurock belumosudil gets conditional marketing authorization on re-exam
Four potential new products and three indication extensions
Discovery & Translation
This week’s translational roundup also includes spatiotemporal degraders, LIMCH1 vesicles in preeclampsia, and three newcos
Regulation
Interpretation of results on a primary endpoint factored into close adcomm vote ahead of 2021 approval, Amgen’s $4B deal for ChemoCentryx
Politics, Policy & Law
Mass. Democrat says CNPV is part of wider pattern of politicization of FDA decisions
Finance
Plus: Third Arc augments series A, Syncona’s Slingshot accelerator houses newly launched ALTx, and more
Plus: Veradermics, SpyGlass enjoy first-day bumps; Generate Bio files for NASDAQ listing
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Management Tracks
BioCentury ISSN 1097-7201